Involvement of IGF-1/IGFBP-3 signaling on the conspicuousness of facial pores.
Conspicuous facial pores are one type of serious esthetic defects for many women. We previously reported that the severity of impairment of skin architecture around facial pores correlates well with the appearance of facial pores in several ethnic groups. In our last report, we showed that serum levels of insulin-like growth factor-1 (IGF-1) correlate well with facial pore size and with the severity of impairment of epidermal architecture around facial pores. However, our results could not fully explain the implication between facial pores and IGF signaling. In this study, we conducted a histological analysis of facial skin to determine whether potential changes in IGF-1 availability occur in the skin with or without conspicuous pores. Immunohistochemical observations showed that expression of insulin-like growth factor binding protein-3 (IGFBP-3) is limited to the suprapapillary epidermis around facial pores and to basal cells of rete pegs without tips in epidermis with conspicuous pores. In contrast, in basal cells of skin without conspicuous pores, IGFBP-3 expression is very low. Ki-67 and IGF-1 receptor-positive cells are abundant in basal cells in the tips of the rete pegs in skin with typical epidermal architecture around facial pores. No obvious differences were observed in the expression of filaggrin, involucrin, K1, K6 or K17 in skin with or without conspicuous pores. However, increased expression of K16 was observed in skin with conspicuous pores suggesting hyperproliferation. These results suggest that the IGF-1/IGFBP-3 signaling pathway is involved in the formation of conspicuous facial pores due to the epidermal architecture around facial pores.
Sugiyama-Nakagiri
Yoriko
Y
Kao Corporation Biological Science Laboratories, Ichikai-Machi, Haga-Gun, Tochigi, Japan. nakagiri.yoriko@kao.co.jp
Ohuchi
Atsushi
A
Hachiya
Akira
A
Kitahara
Takashi
T
D000328:Adult; D000943:Antigens, Differentiation / Q000378:metabolism; D002454:Cell Differentiation; D049109:Cell Proliferation; D005145:Face; D005260:Female; D000091344:Filaggrin Proteins; D006801:Humans; D007150:Immunohistochemistry; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000235:genetics* / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000235:genetics* / Q000378:metabolism; D053536:Keratin-16 / Q000235:genetics / Q000378:metabolism*; D018715:Microscopy, Video; D015398:Signal Transduction; D012867:Skin / Q000378:metabolism* / Q000473:pathology; D012871:Skin Diseases / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology
D000943:Antigens, Differentiation; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D018972:Insulin-Like Growth Factor Binding Protein 3; D053536:Keratin-16; D007334:Insulin-Like Growth Factor I